AI-generated summary
In a study of 24 rats treated with zoledronic acid to induce osteonecrosis, the authors compared bioactive glass and photobiomodulation in skull bone defects. At 14 and 28 days, bioactive glass groups showed higher bone formation than the control group, while adding photobiomodulation did not produce a clear additional benefit. The authors report these findings in an animal model only.
- Participants
- 24
- Who or what was studied
- Rats with zoledronic acid-induced osteonecrosis and surgically created 5-mm calvarial bone defects
- Limits stated in the abstract
- This is an animal study with small groups, and the abstract reports a non-significant result for the bioactive glass plus photobiomodulation group at 28 days.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Purpose
To evaluate the influence of bioactive glass and photobiomodulation therapy (PBMT) in calvarial bone repair process in rats submitted to zoledronic acid therapy.
Methods
Twenty-four rats were selected and treated with the dose of 0.035 mg/kg of zoledronic acid every two weeks, totalizing eight weeks, to induce osteonecrosis. After the drug therapy, surgical procedure was performed to create 5-mm diameter parietal bone defects in the calvarial region. The rats were then randomly assigned to groups according to the following treatments: AZC: control group, treated with blood clot; AZBIO: bone defect filled with bioactive glass; AZL: treated with blood clot and submitted to PBMT; and AZBIOL: treated with bioactive glass S53P4 and submitted to PBMT. Tissue samples were collected and submitted to histomorphometric analysis after 14 and 28 days.
Results
At 14 days, bone neoformation in the AZBIO (52.15 ± 9.77) and AZBIOL (49.77 ± 13.58) groups presented higher values (p ≤ 0.001) compared to the AZC (23.35 ± 10.15) and AZL groups (23.32 ± 8.75). At 28 days, AZBIO (80.24 ± 5.41)still presented significant higher bone recovery values when compared to AZC (59.59 ± 16.92)and AZL (45.25 ± 5.41) groups (p = 0.048). In the 28-day period, the AZBIOL group didn't show statistically significant difference with the other groups (71.79 ± 29.38).
Conclusions
The bioactive glass is an effective protocol to stimulate bone neoformation in critical defects surgically created in rats with drug induced osteonecrosis, in the studied periods of 14 and 28 days.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Low-level laser therapy, Laser, Photobiomodulation, Control group, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.